Developer docs
API playgroundTry for free, no card

Search company profiles

Atavistik Bio

Full company profile

uuid00005ez

Namestring
Atavistik Bio
Legal namestring
Atavistik Bio, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Atavistik Bio is a clinical-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts, that develops precision allosteric small molecule therapeutics for metabolic diseases and cancer. The company's discovery engine is the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, which combines the licensed-in MIDAS technology (mass spectrometry integrated with equilibrium dialysis, developed at the University of Utah by co-founder Jared Rutter and published in Science in 2023), AI-enabled informatics via a partnership with Plex Research, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins that are inaccessible to conventional orthosteric approaches. This platform has generated an internal pipeline led by ATV-1601, an oral allosteric AKT1-selective inhibitor that received FDA IND clearance and Fast Track Designation in June 2026 for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT Phase 1/2 study, and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms currently in lead optimization.

The company targets diseases with high unmet need and no or limited approved therapies: HHT affects more than 1.6 million people globally and 80,000+ in the US, while myeloproliferative neoplasms affect 300,000+ patients in the US with current pan-JAK inhibitors limited by tolerability and inability to suppress mutant allele burden. Atavistik has assembled a senior leadership team with lineage from Blueprint Medicines, Agios Pharmaceuticals, Fulcrum Therapeutics, Servier, and Sage Therapeutics, and is supported by top-tier life sciences investors including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management, with cumulative disclosed funding of approximately $260 million since inception.

Atavistik's business model is a hybrid of internal pipeline development and platform licensing. Revenue, once generated, is expected to come from drug commercialization, milestone payments, and royalties from collaborative agreements. The company advanced a research collaboration with Pfizer in January 2025 to apply the AMPS platform against two undisclosed oncology targets, with Pfizer holding an option to license resulting programs, providing a non-dilutive capital pathway alongside equity financing. The company is pre-revenue, has no commercial products, and channels outputs through traditional pharmaceutical distribution upon regulatory approval or via licensing to larger partners.

Short descriptiontext

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for Hereditary Hemorrhagic Telangiectasia, myeloproliferative neoplasms, and oncology using its proprietary AMPS metabolite-protein screening platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allosteric small molecules, precision oncology therapeutics, rare hematology treatments, metabolite-protein screening platform, structure-based drug design
Industry1 code
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Allosteric Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Future Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical stage biotechnology company. Plans to develop and commercialize novel allosteric therapeutics internally and through licensing partnerships. Revenue will come from drug sales, milestone payments, and royalties from collaborative agreements.

atavistikbio.com
2Collaborations and Licensing
TypeLicensing Royalties
Description

Strategic partnerships with pharmaceutical companies for platform utilization and program licensing. Pfizer collaboration for oncology targets represents a licensing model where Pfizer can license programs after research period. Atavistik retains internal pipeline development rights while extending platform reach through partnerships.

atavistikbio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for metabolic diseases and cancer. Its lead asset, ATV-1601, is an oral AKT1-selective inhibitor in Phase 1/2 for Hereditary Hemorrhagic Telangiectasia (HHT), with a JAK2 V617F mutant-selective inhibitor program in lead optimization for myeloproliferative neoplasms (MPNs). Discovery is powered by the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform that combines metabolite-protein screening, AI-enabled analysis, and structure-based drug design.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ATV-1601 demonstrated favorable safety profile in Phase 1 oncology study, validating differentiated selectivity over pan-AKT inhibitors
+2 more records
Product overview1 text field

Atavistik Bio is a clinical stage biotechnology company developing a portfolio of selective allosteric therapeutics. The company's core product is ATV-1601, an oral allosteric AKT1-selective inhibitor currently in Phase 1/2 clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT study. The pipeline also includes a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms in lead optimization stage. The AMPS (Atavistik Metabolite-Protein Screening) platform serves as the foundational technology enabling the discovery of these allosteric therapeutics by leveraging metabolite-protein interactions, AI-enabled analysis, and structure-based drug design. Internal development focuses on rare hematology, while strategic partnerships (including with Pfizer in oncology) extend the platform's reach across therapeutic areas.

Product and service3 records
1ATV-1601
CategoryDrug Candidate / Lead Asset
Description

Oral allosteric AKT1-selective inhibitor being evaluated for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder. Designed to selectively target AKT1 to address vascular pathology across ALK1, ENG, and SMAD4 mutations.

2JAK2 V617F Mutant-Selective Inhibitor Program
CategoryDrug Candidate / Pipeline Program
Description

Allosteric inhibitor program targeting the JAK2 V617F mutation for myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and myelofibrosis). Binds the pseudokinase JH2 domain to selectively inhibit mutant JAK2 while sparing wild-type JAK2.

3AMPS (Atavistik Metabolite-Protein Screening) Platform
CategoryDrug Discovery Platform / Technology Offering
Description

Proprietary drug discovery platform combining metabolite-protein interaction screening, AI-enabled discovery, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins. Leveraged internally for pipeline development and offered to pharmaceutical partners through research collaborations and licensing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-02
Description

Research collaboration where Atavistik Bio leverages its proprietary AMPS platform to identify novel allosteric binders against two undisclosed Pfizer-designated oncology targets. At completion of research period, Pfizer has option to license the programs. Collaboration enables Atavistik to extend platform reach to broader oncology indications while progressing internal pipeline.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Precision medicine biotech focused on kinase inhibitors for oncology and rare diseases. Most directly comparable given shared leadership lineage (Atavistik's CSO Marion Dorsch was previously CSO at Blueprint Medicines) and similar allosteric/inhibitor approach to historically intractable targets.

TypeDirect peer
Description

Metabolism-focused drug discovery company developing therapies for cancer and rare genetic diseases. Multiple Atavistik senior leaders are Agios alumni (CSO, VP Biology, VP Platform, VP Regulatory, VP Clinical Science), and the metabolism-based approach to drug discovery is highly aligned.

TypeDirect peer
Description

Precision oncology company developing allosteric inhibitors of key oncogenic drivers. Directly comparable for its allosteric approach to difficult oncology targets and its emphasis on selective modulation of disease-causing proteins.

TypeDirect peer
Description

Precision medicine company using motion-based structural insights and computational chemistry to design allosteric and selective inhibitors. Comparable for its emphasis on allosteric targeting and platform-enabled precision oncology discovery.

TypeDirect peer
Description

Precision oncology company developing allosteric inhibitors across multiple targets. Comparable for its allosteric approach to difficult-to-drug oncogenic targets and its platform-driven pipeline strategy.

TypeDirect peer
Description

Precision oncology company targeting chromatin regulatory complexes. Comparable for its platform-enabled discovery of selective modulators against historically intractable oncology targets and similar scientific approach to protein modulation.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for genetically defined rare diseases. Atavistik's CEO Bryan Stuart was previously CEO of Fulcrum, and the companies share rare-disease focus with selective small-molecule approaches.

TypeDirect peer
Description

Precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable for its emphasis on selective targeting of historically intractable oncology targets and clinical-stage development.

TypeEmerging player
Description

Computational drug discovery platform company combining physics-based simulation with AI/ML to accelerate small molecule discovery. Comparable for its platform-based business model combining computational tools with therapeutic programs, though broader in scope than Atavistik's metabolite-protein focus.

TypeEmerging player
Description

AI-enabled drug discovery company combining high-throughput experimental biology with machine learning. Comparable for its AI-driven discovery platform approach, though Atavistik focuses specifically on metabolite-protein interactions while Recursion uses image-based phenotypic screening.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atavistik Bio

Precision Allosteric Therapeuticsatavistikbio.com

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for Hereditary Hemorrhagic Telangiectasia, myeloproliferative neoplasms, and oncology using its proprietary AMPS metabolite-protein screening platform.

What Atavistik Bio does

Atavistik Bio is a clinical-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts, that develops precision allosteric small molecule therapeutics for metabolic diseases and cancer. The company's discovery engine is the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, which combines the licensed-in MIDAS technology (mass spectrometry integrated with equilibrium dialysis, developed at the University of Utah by co-founder Jared Rutter and published in Science in 2023), AI-enabled informatics via a partnership with Plex Research, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins that are inaccessible to conventional orthosteric approaches. This platform has generated an internal pipeline led by ATV-1601, an oral allosteric AKT1-selective inhibitor that received FDA IND clearance and Fast Track Designation in June 2026 for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT Phase 1/2 study, and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms currently in lead optimization.

The company targets diseases with high unmet need and no or limited approved therapies: HHT affects more than 1.6 million people globally and 80,000+ in the US, while myeloproliferative neoplasms affect 300,000+ patients in the US with current pan-JAK inhibitors limited by tolerability and inability to suppress mutant allele burden. Atavistik has assembled a senior leadership team with lineage from Blueprint Medicines, Agios Pharmaceuticals, Fulcrum Therapeutics, Servier, and Sage Therapeutics, and is supported by top-tier life sciences investors including The Column Group, Nextech Invest, Lux Capital, Regeneron Ventures, and RA Capital Management, with cumulative disclosed funding of approximately $260 million since inception.

Atavistik's business model is a hybrid of internal pipeline development and platform licensing. Revenue, once generated, is expected to come from drug commercialization, milestone payments, and royalties from collaborative agreements. The company advanced a research collaboration with Pfizer in January 2025 to apply the AMPS platform against two undisclosed oncology targets, with Pfizer holding an option to license resulting programs, providing a non-dilutive capital pathway alongside equity financing. The company is pre-revenue, has no commercial products, and channels outputs through traditional pharmaceutical distribution upon regulatory approval or via licensing to larger partners.

Atavistik Bio firmographics

Firmographics
Name
Atavistik Bio
Legal name
Atavistik Bio, Inc.
Website
https://atavistikbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for Hereditary Hemorrhagic Telangiectasia, myeloproliferative neoplasms, and oncology using its proprietary AMPS metabolite-protein screening platform.
Ownership category
akta.pro rank

Atavistik Bio industry classification

Industry
Product category
Precision Allosteric Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Allosteric small molecules
  • Precision oncology therapeutics
  • Rare hematology treatments
  • Metabolite-protein screening platform
  • Structure-based drug design

Where Atavistik Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Atavistik Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Future Drug Development and Commercialization: Pre-revenue clinical stage biotechnology company. Plans to develop and commercialize novel allosteric therapeutics internally and through licensing partnerships. Revenue will come from drug sales, milestone payments, and royalties from collaborative agreements.
  2. Collaborations and Licensing: Strategic partnerships with pharmaceutical companies for platform utilization and program licensing. Pfizer collaboration for oncology targets represents a licensing model where Pfizer can license programs after research period. Atavistik retains internal pipeline development rights while extending platform reach through partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Atavistik Bio product offering

Product offering

Core offering

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for metabolic diseases and cancer. Its lead asset, ATV-1601, is an oral AKT1-selective inhibitor in Phase 1/2 for Hereditary Hemorrhagic Telangiectasia (HHT), with a JAK2 V617F mutant-selective inhibitor program in lead optimization for myeloproliferative neoplasms (MPNs). Discovery is powered by the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform that combines metabolite-protein screening, AI-enabled analysis, and structure-based drug design.

Product overview

Atavistik Bio is a clinical stage biotechnology company developing a portfolio of selective allosteric therapeutics. The company's core product is ATV-1601, an oral allosteric AKT1-selective inhibitor currently in Phase 1/2 clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT) under the Harmony-HHT study. The pipeline also includes a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms in lead optimization stage. The AMPS (Atavistik Metabolite-Protein Screening) platform serves as the foundational technology enabling the discovery of these allosteric therapeutics by leveraging metabolite-protein interactions, AI-enabled analysis, and structure-based drug design. Internal development focuses on rare hematology, while strategic partnerships (including with Pfizer in oncology) extend the platform's reach across therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATV-1601 Oral allosteric AKT1-selective inhibitor being evaluated for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder. Designed to selectively target AKT1 to address vascular pathology across ALK1, ENG, and SMAD4 mutations.
  • JAK2 V617F Mutant-Selective Inhibitor Program Allosteric inhibitor program targeting the JAK2 V617F mutation for myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, and myelofibrosis). Binds the pseudokinase JH2 domain to selectively inhibit mutant JAK2 while sparing wild-type JAK2.
  • AMPS (Atavistik Metabolite-Protein Screening) Platform Proprietary drug discovery platform combining metabolite-protein interaction screening, AI-enabled discovery, and structure-based drug design to systematically identify functional allosteric binding pockets on disease-relevant proteins. Leveraged internally for pipeline development and offered to pharmaceutical partners through research collaborations and licensing.

Quantifiable outcome

  • ATV-1601 demonstrated favorable safety profile in Phase 1 oncology study, validating differentiated selectivity over pan-AKT inhibitors
  • +2 more outcomes

Companies that use Atavistik Bio

Customer profile

Segments3 records

Ideal customer profiles1 record

Atavistik Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Atavistik Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • PfizercoreStrategic or Co-development Partner · 2 January 2025Research collaboration where Atavistik Bio leverages its proprietary AMPS platform to identify novel allosteric binders against two undisclosed Pfizer-designated oncology targets. At completion of research period, Pfizer has option to license the programs. Collaboration enables Atavistik to extend platform reach to broader oncology indications while progressing internal pipeline.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Atavistik Bio competitors and assessment

Company assessment

Direct peers

  • Blueprint Medicines: Precision medicine biotech focused on kinase inhibitors for oncology and rare diseases. Most directly comparable given shared leadership lineage (Atavistik's CSO Marion Dorsch was previously CSO at Blueprint Medicines) and similar allosteric/inhibitor approach to historically intractable targets.
  • Agios Pharmaceuticals: Metabolism-focused drug discovery company developing therapies for cancer and rare genetic diseases. Multiple Atavistik senior leaders are Agios alumni (CSO, VP Biology, VP Platform, VP Regulatory, VP Clinical Science), and the metabolism-based approach to drug discovery is highly aligned.
  • Revolution Medicines: Precision oncology company developing allosteric inhibitors of key oncogenic drivers. Directly comparable for its allosteric approach to difficult oncology targets and its emphasis on selective modulation of disease-causing proteins.
  • Relay Therapeutics: Precision medicine company using motion-based structural insights and computational chemistry to design allosteric and selective inhibitors. Comparable for its emphasis on allosteric targeting and platform-enabled precision oncology discovery.
  • Black Diamond Therapeutics: Precision oncology company developing allosteric inhibitors across multiple targets. Comparable for its allosteric approach to difficult-to-drug oncogenic targets and its platform-driven pipeline strategy.
  • Foghorn Therapeutics: Precision oncology company targeting chromatin regulatory complexes. Comparable for its platform-enabled discovery of selective modulators against historically intractable oncology targets and similar scientific approach to protein modulation.
  • Fulcrum Therapeutics: Clinical-stage biopharmaceutical company developing therapies for genetically defined rare diseases. Atavistik's CEO Bryan Stuart was previously CEO of Fulcrum, and the companies share rare-disease focus with selective small-molecule approaches.
  • Erasca: Precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable for its emphasis on selective targeting of historically intractable oncology targets and clinical-stage development.

Emerging players

  • Schrödinger: Computational drug discovery platform company combining physics-based simulation with AI/ML to accelerate small molecule discovery. Comparable for its platform-based business model combining computational tools with therapeutic programs, though broader in scope than Atavistik's metabolite-protein focus.
  • Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-throughput experimental biology with machine learning. Comparable for its AI-driven discovery platform approach, though Atavistik focuses specifically on metabolite-protein interactions while Recursion uses image-based phenotypic screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Atavistik Bio social profiles

Digital presence

Atavistik Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atavistik Bio leadership team

Management profile

Number of profiles

Profiles16 records

Atavistik Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atavistik Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atavistik Bio

What does Atavistik Bio do?

Atavistik Bio is a clinical-stage biotechnology company developing precision allosteric small molecule therapeutics for metabolic diseases and cancer. Its lead asset, ATV-1601, is an oral AKT1-selective inhibitor in Phase 1/2 for Hereditary Hemorrhagic Telangiectasia (HHT), with a JAK2 V617F mutant-selective inhibitor program in lead optimization for myeloproliferative neoplasms (MPNs). Discovery is powered by the proprietary AMPS (Atavistik Metabolite-Protein Screening) platform that combines metabolite-protein screening, AI-enabled analysis, and structure-based drug design.

Is Atavistik Bio a public or private company?

Atavistik Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Atavistik Bio founded?

Atavistik Bio was founded in 2021. It employs 11 to 50 people.

Where is Atavistik Bio based?

Atavistik Bio is headquartered in Cambridge, United States, in the North America region.

How does Atavistik Bio make money?

Two revenue lines are on record. Future Drug Development and Commercialization is the primary driver. The others are collaborations and Licensing.

Who are Atavistik Bio's main competitors?

Direct peers on record are Blueprint Medicines, Agios Pharmaceuticals, Revolution Medicines, Relay Therapeutics, Black Diamond Therapeutics, Foghorn Therapeutics, Fulcrum Therapeutics and Erasca. Emerging players are Schrödinger and Recursion Pharmaceuticals.

Does Atavistik Bio have an API?

No public API is recorded for Atavistik Bio.

What industry is Atavistik Bio in?

Atavistik Bio's product category is Precision Allosteric Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterAtavistik Bio enters research collaboration with RocheAtavistik Bio and Roche entered a strategic research collaboration to discover and develop novel small molecule therapeutics for cardiovascular, renal, and metabolic diseases. The partnership will leverage Atavistik's AMPS drug discovery platform to identify cryptic binding pockets and advance selective small molecules against challenging targets.European BiotechnologyRoche signs two deals worth about $3.5B in one dayRoche signed two research partnerships on Sept. 24 with Atavistik Bio and Earendil Labs, totaling over $3.47 billion in potential value. Roche paid $125 million upfront, with Atavistik receiving $70 million and Earendil $55 million. The deals are Roche's fourth and fifth biotech agreements in less than a month.The Times of IndiaRoche signs drug-discovery deal with Atavistik Bio worth up to $2 billionRoche signed a drug-discovery deal with Atavistik Bio worth up to $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney, and metabolic diseases. Atavistik will receive $70 million upfront and could earn up to $1.9 billion in milestones plus royalties. The partnership uses Atavistik's proprietary technology to target hidden protein sites.GlobeNewswireAtavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic TelangiectasiaAtavistik Bio announced a partnership with the Cure HHT Clinical Trial Network to support clinical development of ATV-1601, an investigational oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia. The first clinical site in the Harmony-HHT Phase 1/2 study has been activated at Massachusetts General Hospital, marking a milestone in the advancement of the program. HHT is a rare inherited bleeding disorder affecting over 80,000 people in the US and 1.6 million globally, with no approved therapies currently available, and ATV-1601 has received FDA Fast Track designation.BioSpaceNew funding, new jobs: 4 biotechs hiring after series B raisesFour biotech companies announced series B financing rounds and are actively hiring to support pipeline advancement: Atavistik Bio raised a $40M extension bringing its total round to $160M, Nura Bio raised $73.8M, Pinnacle Medicines raised $89M, and SonoThera raised $125M. The companies are using proceeds to advance clinical programs across therapeutic areas including allosteric therapeutics, neurological diseases, oral peptides, and ultrasound-mediated genetic medicines. All four firms expect to initiate or continue human clinical trials within the next few years.BioSpaceAtavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic TelangiectasiaAtavistik Bio joined the Cure HHT Clinical Trial Network and activated its first clinical site at Massachusetts General Hospital for the Harmony-HHT Phase 1/2 trial of ATV-1601. The oral AKT1 inhibitor targets HHT, a bleeding disorder affecting over 80,000 US patients, with no approved therapies. The trial is FDA Fast Track designated.BioSpaceAtavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)Atavistik Bio announced FDA clearance of its IND for ATV-1601 in the Harmony-HHT Phase 1/2 trial and Fast Track Designation. The oral AKT1 inhibitor targets all HHT driver mutations, with no approved therapies for the disorder affecting over 80,000 U.S. patients.Labiotech.euNext-generation allosteric modulators: A glance at the biotech pipeline in 2026Several biotech companies are advancing allosteric modulator candidates through clinical development, with recent milestones including Rapport Therapeutics reporting positive phase 2a results for RAP-219 in focal onset seizures and planning a phase 3 program for Q2 2026. Atavistik Bio raised $160 million in series B funding to advance ATV-1601 for Hereditary Hemorrhagic Telangiectasia, while Gain Therapeutics reported positive phase 1b data for GT-02287 in Parkinson's disease. Additional developments include Neurosterix initiating a phase 1 study of NTX-253 for schizophrenia and Axsome Therapeutics acquiring global rights to the allosteric modulator AXS-17 through its purchase of Baergic Bio.The Pharma LetterAtavistik Bio closes $40 million Series B extensionCambridge-based precision allosteric therapeutics biotech Atavistik Bio has closed a $40 million extension to its Series B financing round from new investor RA Capital Management, bringing the total Series B proceeds to $160 million. The funding will support the company's advancement of its precision allosteric therapeutics pipeline. This represents a significant capital raise for an early-to-mid stage biotech company in the precision medicine space.GlobeNewswireAtavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 MillionAtavistik Bio closed a $40 million Series B extension from RA Capital Management, bringing total round proceeds to $160 million. The funds will advance ATV-1601, an AKT1-selective inhibitor for HHT, and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept.